Bifunctional Compounds Targeting SMARCA2 via CRBN Ligase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for SMARCA2-mediated disorders, particularly cancers, face challenges due to the difficulty in targeting and modulating SMARCA2 protein effectively, given its role in cancer development and the lack of specific therapeutic agents that leverage CRBN's substrate specificity.
Innovation Solution
Development of bifunctional compounds that specifically target SMARCA2 by binding to a targeting ligand, linked through a linker to a degron, facilitating its ubiquitination and proteasomal degradation via cereblon (CRBN) E3 ubiquitin ligase, thereby degrading SMARCA2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bifunctional compounds are designed to target SMARCA2 via CRBN E3 ligase, then specificity for SMARCA2 degradation is improved, but the complexity of the compound structure increases
Solution Approach 1:
The bifunctional compound is divided into two distinct functional modules: a CRBN-binding moiety (degron) that recruits the E3 ligase, and a SMARCA2-binding ligand that provides target specificity. These modules are connected by a linker, allowing each component to perform its function independently while working together to achieve selective SMARCA2 degradation via ubiquitination
Solution Approach 2:
The CRBN E3 ligase serves as an intermediary protein that bridges the bifunctional compound and the SMARCA2 target. The compound recruits CRBN to the SMARCA2 complex, and CRBN mediates the ubiquitination process, thereby indirectly targeting SMARCA2 for degradation without requiring direct binding between the compound and SMARCA2
2Reliability
If small molecules are used to target protein-protein interactions, then the ability to modulate SMARCA2 is improved, but the difficulty in achieving effective targeting increases due to large contact surfaces
Solution Approach 1:
The patent employs CRBN E3 ligase as an intermediary mediator to overcome the difficulty of directly targeting the large protein-protein interaction interface of SMARCA2. The bifunctional compound binds to CRBN, which then interacts with the SMARCA2-containing SWI/SNF complex, thereby indirectly modulating SMARCA2 function through a more accessible binding surface on CRBN
Solution Approach 2:
The invention leverages the cell's own ubiquitin-proteasome system and the endogenous CRBN E3 ligase to achieve SMARCA2 degradation. Rather than introducing external degradation machinery, the compound hijacks the cell's existing protein degradation pathways, allowing the system to degrade SMARCA2 using its own resources
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively degrade SMARCA2, offering a potential therapeutic approach for SMARCA2-mediated disorders, including cancers, by leveraging CRBN's substrate specificity to induce targeted protein degradation.
Implementation Method 1
The compounds of the present invention cause the degradation of SMARCA2 via the targeted ubiquitination of SMARCA2 protein and subsequent proteasomal degradation
Data Source
AI summary
The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).